Asthma management has gradually evolved from a ‘’one-size-fits-all’’ concept into a more personalised approach . While the majority of patients with mild-to-moderate and uncomplicated asthma reach optimal control with ICS-containing therapy, a significant minority with more severe disease fails to reach (optimal) control with ICS as a result of the underlying immuno-patho(physio)logy requiring a personalised approach with targeted therapy guided by biomarkers [3, 7, 8].
Interestingly, guidelines for severe asthma management do not yet insist on standard evaluation of the airway inflammatory components to guide treatment, although the nature of the airway inflammation clearly drives the choice of targeted therapy .
For type2 asthma, several add-on treatments targeting different inflammatory pathways are currently available, while several new drugs are in different stages of clinical development (Figure 2) . For patients with a strong allergic component (hist...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: ERS 2018
COPD: Triple therapy, MABA and antibiotics
Current look on asthma
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.